- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01396187
Safety and Tolerability of Ascending Intravenous Doses of PF-05231023 In Adult Subjects With Type 2 Diabetes
30. desember 2014 oppdatert av: Pfizer
A Phase 1, Placebo-Controlled Randomized Trial To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Multiple Ascending Intravenous Doses Of PF-05231023 In Adult Subjects With Type 2 Diabetes Mellitus
This is a trial in subjects with Type 2 diabetes mellitus to study the safety, tolerability and pharmacokinetics of multiple ascending doses of PF-05231023.
Studieoversikt
Status
Fullført
Forhold
Intervensjon / Behandling
Studietype
Intervensjonell
Registrering (Faktiske)
50
Fase
- Fase 1
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
California
-
Chula Vista, California, Forente stater, 91911
- Pfizer Investigational Site
-
-
Florida
-
Miami, Florida, Forente stater, 33169
- Pfizer Investigational Site
-
South Miami, Florida, Forente stater, 33143
- Pfizer Investigational Site
-
-
Kansas
-
Overland Park, Kansas, Forente stater, 66212
- Pfizer Investigational Site
-
-
Texas
-
San Antonio, Texas, Forente stater, 78229
- Pfizer Investigational Site
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
30 år til 70 år (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Male subjects and female subjects of non-childbearing potential between the ages of 30 and 70 years, inclusive, with a historical diagnosis of type 2 diabetes mellitus, diagnosed according to the American Diabetes Association guidelines. Subjects who have other conditions but are well controlled by either diet or medications may be included as well (for example, a subject with high cholesterol level on appropriate treatment is eligible).
- Body Mass Index (BMI) of 25 to 35.5 kg/m2, and a total body weight >50 kg (110 lbs).
Exclusion Criteria:
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
- Diagnosis of Type 1 diabetes mellitus.
- Evidence of diabetic complications with significant end organ damage
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Trippel
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Placebo komparator: Placebo
|
0.9% w/v sodium chloride injection, United States Pharmacopeia (USP), twice a week IV for 4 weeks
|
Eksperimentell: Behandling
|
5 mg IV twice a week for 4 weeks
25 mg IV twice a week for 4 weeks
100 mg IV twice a week for 4 weeks
200 mg IV twice a week for 4 weeks
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Number of Participants With Abnormal Physical Examination Findings
Tidsramme: Baseline up to Day 42
|
Physical examination included assessment of height, weight, blood pressure, pulse rate and body temperature.
Criteria for abnormal physical findings was based on investigator's discretion and were reported as adverse event (AE), as planned.
|
Baseline up to Day 42
|
Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)
Tidsramme: Baseline up to Day 77
|
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Treatment-emergent are events between first dose of study drug and up to Day 77 which were absent before treatment or that worsened relative to pretreatment state.
|
Baseline up to Day 77
|
Number of Participants With Abnormal Laboratory Values
Tidsramme: Baseline up to Day 42
|
Criteria for laboratory tests abnormalities included: hemoglobin, hematocrit and red blood cells (RBCs)(less than [<] 0.8*lower limit of normal[LLN]); leucocytes (<0.6/greater than [>]1.5*upper
limit of normal [ULN]); platelets (<0.5*LLN></0>1.75*ULN);
neutrophils, lymphocytes (<0.8*LLN></0>1.2*ULN);
eosinophils, basophils, monocytes (>1.2*ULN); total bilirubin, direct bilirubin, indirect bilirubin (>1.5*ULN); aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (>3*ULN), total protein, albumin (<0.8*LLN></0>1.2*ULN);
creatinine, urea (>1.3*ULN); glucose (<0.6*LLN></0>1.5*ULN);
uric acid (>1.2*ULN); sodium, potassium, chloride, calcium, bicarbonate (<0.9*LLN></0>1.1*ULN);
urine RBCs, urine white blood cells (WBCs) (> or equal[=]20 high-powered field), urine bacteria >20 high-powered field.
Total number of participants with any laboratory abnormalities were reported.
|
Baseline up to Day 42
|
Number of Participants With Vital Signs Abnormalities
Tidsramme: Baseline up to Day 77
|
Criteria for vital signs abnormalities: supine systolic blood pressure (SBP) <90 millimeter of mercury (mm Hg), supine diastolic BP (DBP) <50 mm Hg, supine pulse rate <40 beats per minute (bpm), > 120 bpm.
Maximum increase or decrease from baseline in supine SBP >=30 mm Hg and maximum increase or decrease from baseline in supine DBP >=20 mm Hg.
|
Baseline up to Day 77
|
Number of Participants With Electrocardiogram (ECG) Abnormalities
Tidsramme: Baseline up to Day 77
|
Criteria for potential clinical concern in ECG parameters: maximum PR interval of greater than or equal to (>=) 300 milliseconds (msec), maximum QRS interval >=140 msec, maximum QTCF interval (Fridericia's Correction) of 450 to <480 msec, 480 to <500 msec and >=500 msec, maximum increase of >=25 percent (%) for baseline value of >200 msec and >=50% for baseline value of less than or equal to (<=) 200 msec for PR interval, maximum increase from baseline of >=50% for QRS interval, maximum increase from baseline of >=30 msec to <60 msec and maximum increase from baseline of >60 msec in QTCF interval (Fridericia's Correction).
|
Baseline up to Day 77
|
Number of Participants With Blood Glucose Abnormalities
Tidsramme: Baseline up to Day 32
|
Criteria for blood glucose abnormality: Blood glucose levels <0.6* LLN or >1.5* ULN.
|
Baseline up to Day 32
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-05231023 After Single Dose
Tidsramme: 0 hour (pre-dose) on Day 1, 4; 0.5, 1 (end of infusion), 1.5, 2, 3, 5, 9, 13 hours post-start of infusion on Day 1; Day 2, 3
|
Participants who received PF-05231023 with C-terminal and N-terminal AUCtau were reported.
|
0 hour (pre-dose) on Day 1, 4; 0.5, 1 (end of infusion), 1.5, 2, 3, 5, 9, 13 hours post-start of infusion on Day 1; Day 2, 3
|
Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-05231023 After Single Dose
Tidsramme: 0 hour (pre-dose) on Day 1, 4; 0.5, 1 (end of infusion), 1.5, 2, 3, 5, 9, 13 hours post-start of infusion on Day 1; Day 2, 3
|
Participants who received PF-05231023 with C-terminal and N-terminal Tmax were reported.
|
0 hour (pre-dose) on Day 1, 4; 0.5, 1 (end of infusion), 1.5, 2, 3, 5, 9, 13 hours post-start of infusion on Day 1; Day 2, 3
|
Maximum Observed Plasma Concentration (Cmax) of PF-05231023 After Single Dose
Tidsramme: 0 hour (pre-dose) on Day 1, 4; 0.5, 1 (end of infusion), 1.5, 2, 3, 5, 9, 13 hours post-start of infusion on Day 1; Day 2, 3
|
Participants who received PF 05231023 with C-terminal and N-terminal Cmax were reported.
|
0 hour (pre-dose) on Day 1, 4; 0.5, 1 (end of infusion), 1.5, 2, 3, 5, 9, 13 hours post-start of infusion on Day 1; Day 2, 3
|
Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-05231023 at Steady State
Tidsramme: 0 hour (pre-dose) 0.5, 1 (end of infusion), 1.5, 2, 3, 5, 9, 13 hours post-start of infusion on Day 25; Day 26, 29
|
Participants who received PF-05231023 with C-terminal and N-terminal AUCtau at steady state were reported.
|
0 hour (pre-dose) 0.5, 1 (end of infusion), 1.5, 2, 3, 5, 9, 13 hours post-start of infusion on Day 25; Day 26, 29
|
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-05231023 at Steady State
Tidsramme: 0 hour (pre-dose) 0.5, 1 (end of infusion), 1.5, 2, 3, 5, 9, 13 hours post-start of infusion on Day 25; Day 26, 29
|
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast) at steady state.
Participants who received PF-05231023 with C-terminal and N-terminal AUClast at steady state were reported.
|
0 hour (pre-dose) 0.5, 1 (end of infusion), 1.5, 2, 3, 5, 9, 13 hours post-start of infusion on Day 25; Day 26, 29
|
Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-05231023 at Steady State
Tidsramme: 0 hour (pre-dose) 0.5, 1 (end of infusion), 1.5, 2, 3, 5, 9, 13 hours post-start of infusion on Day 25; Day 26, 29
|
Participants who received PF-05231023 with C-terminal and N-terminal Tmax at steady state were reported.
|
0 hour (pre-dose) 0.5, 1 (end of infusion), 1.5, 2, 3, 5, 9, 13 hours post-start of infusion on Day 25; Day 26, 29
|
Maximum Observed Plasma Concentration (Cmax) of PF-05231023 at Steady State
Tidsramme: 0 hour (pre-dose) 0.5, 1 (end of infusion), 1.5, 2, 3, 5, 9, 13 hours post-start of infusion on Day 25; Day 26, 29
|
Participants who received PF 05231023 with C-terminal and N-terminal Cmax at steady state were reported.
|
0 hour (pre-dose) 0.5, 1 (end of infusion), 1.5, 2, 3, 5, 9, 13 hours post-start of infusion on Day 25; Day 26, 29
|
Accumulation Ratio for Area Under the Curve From Time Zero to End of Dosing Interval of PF-05231023 (Rac)
Tidsramme: 0 hour (pre-dose) on Day 1, 4, 25; 0.5, 1 (end of infusion), 1.5, 2, 3, 5, 9, 13 hours post-start of infusion on Day 1, 25; Day 2, 3, 26, 29
|
Rac was obtained from AUCtau at steady state (Day 25) divided by AUCtau after single dose (Day 1).
AUCtau was the area under the concentration-time profile from time zero to end of dosing interval, where tau = 72 hours for Day 1 and tau = 96 hours for Day 25.
Participants who received PF-05231023 with C-terminal and N-terminal Rac at steady state were reported.
|
0 hour (pre-dose) on Day 1, 4, 25; 0.5, 1 (end of infusion), 1.5, 2, 3, 5, 9, 13 hours post-start of infusion on Day 1, 25; Day 2, 3, 26, 29
|
Accumulation Ratio for Maximum Observed Plasma Concentration (Rac,Cmax) of PF- 05231023
Tidsramme: 0 hour (pre-dose) on Day 1, 4, 25; 0.5, 1 (end of infusion), 1.5, 2, 3, 5, 9, 13 hours post-start of infusion on Day 1, 25; Day 2, 3, 26, 29
|
Accumulation ratio based on maximum plasma concentration (Cmax) was calculated as: Rac,Cmax = Cmax at steady state (Day 25) divided by Cmax at first dose (Day 1).
Participants who received PF-05231023 with C-terminal and N-terminal Rac,Cmax at steady state were reported.
|
0 hour (pre-dose) on Day 1, 4, 25; 0.5, 1 (end of infusion), 1.5, 2, 3, 5, 9, 13 hours post-start of infusion on Day 1, 25; Day 2, 3, 26, 29
|
Plasma Terminal Half-Life (t1/2) of PF-05231023 at Steady State
Tidsramme: 0 hour (pre-dose) 0.5, 1 (end of infusion), 1.5, 2, 3, 5, 9, 13 hours post-start of infusion on Day 25; Day 26, 29
|
Plasma terminal half-life is the time measured for the plasma concentration to decrease by one half at the terminal phase.
Participants who received PF-05231023 with C-terminal and N-terminal t1/2 at steady state were reported.
|
0 hour (pre-dose) 0.5, 1 (end of infusion), 1.5, 2, 3, 5, 9, 13 hours post-start of infusion on Day 25; Day 26, 29
|
Apparent Clearance (CL) of PF-05231023 at Steady State
Tidsramme: 0 hour (pre-dose) 0.5, 1 (end of infusion), 1.5, 2, 3, 5, 9, 13 hours post-start of infusion on Day 25; Day 26, 29
|
Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
Participants who received PF-05231023 with C-terminal and N-terminal CL at steady state were reported.
|
0 hour (pre-dose) 0.5, 1 (end of infusion), 1.5, 2, 3, 5, 9, 13 hours post-start of infusion on Day 25; Day 26, 29
|
Volume of Distribution of PF-05231023 at Steady State (Vss)
Tidsramme: 0 hour (pre-dose) 0.5, 1 (end of infusion), 1.5, 2, 3, 5, 9, 13 hours post-start of infusion on Day 25; Day 26, 29
|
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.
Vss is the apparent volume of distribution at steady-state.
PF-05231023 with C-terminal and N-terminal Vss at steady state were reported.
|
0 hour (pre-dose) 0.5, 1 (end of infusion), 1.5, 2, 3, 5, 9, 13 hours post-start of infusion on Day 25; Day 26, 29
|
Minimum Observed Plasma Trough Concentration (Cmin) of PF-05231023 at Steady State
Tidsramme: 0 hour (pre-dose) 0.5, 1 (end of infusion), 1.5, 2, 3, 5, 9, 13 hours post-start of infusion on Day 25; Day 26, 29
|
Participants who received PF 05231023 with C-terminal and N-terminal Cmax at steady state were reported.
|
0 hour (pre-dose) 0.5, 1 (end of infusion), 1.5, 2, 3, 5, 9, 13 hours post-start of infusion on Day 25; Day 26, 29
|
Average Plasma Concentration (Cav) of PF-05231023 at Steady State
Tidsramme: 0 hour (pre-dose) 0.5, 1 (end of infusion), 1.5, 2, 3, 5, 9, 13 hours post-start of infusion on Day 25; Day 26, 29
|
Participants who received PF-05231023 with C-terminal and N-terminal Cmax at steady state were reported.
|
0 hour (pre-dose) 0.5, 1 (end of infusion), 1.5, 2, 3, 5, 9, 13 hours post-start of infusion on Day 25; Day 26, 29
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Publikasjoner og nyttige lenker
Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.
Hjelpsomme linker
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart
1. juli 2011
Primær fullføring (Faktiske)
1. mai 2012
Studiet fullført (Faktiske)
1. mai 2012
Datoer for studieregistrering
Først innsendt
6. juli 2011
Først innsendt som oppfylte QC-kriteriene
14. juli 2011
Først lagt ut (Anslag)
18. juli 2011
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
12. januar 2015
Siste oppdatering sendt inn som oppfylte QC-kriteriene
30. desember 2014
Sist bekreftet
1. desember 2014
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- B2901002
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Diabetes mellitus, type 2
-
AstraZenecaRekruttering
-
Daewoong Pharmaceutical Co. LTD.Har ikke rekruttert ennåT2DM (type 2 diabetes mellitus)
-
Zhongda HospitalRekrutteringType 2 diabetes mellitus (T2DM)Kina
-
Newsoara Biopharma Co., Ltd.RekrutteringT2DM (type 2 diabetes mellitus)Kina
-
Shanghai Golden Leaf MedTec Co. LtdAktiv, ikke rekrutterendeType 2 diabetes mellitus (T2DM)Kina
-
SanofiFullført
-
Haisco Pharmaceutical Group Co., Ltd.Fullført
-
PegBio Co., Ltd.FullførtType 2 diabetes mellitus (T2DM)Kina
-
Oramed, Ltd.IntegriumAvsluttetT2DM (type 2 diabetes mellitus)Forente stater
-
Oramed, Ltd.IntegriumFullførtT2DM (type 2 diabetes mellitus)Forente stater
Kliniske studier på PF-05231023
-
PfizerFullførtDiabetes meliuts, type 2Forente stater
-
PfizerAvsluttet
-
PfizerFullført
-
University of FloridaFullførtGastrointestinale symptomer | Avføringsfrekvens | Gastrointestinal transitttidForente stater
-
PfizerFullført
-
PfizerFullført
-
PfizerFullført
-
PfizerFullført